SCHEMBL4357679

SCHEMBL4357679

Oc1c(F)cc(Br)cc1NC(=S)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.51
LMNA P02545 3/20 0.46
HPGD P15428 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
ALOX12 P18054 1/20 0.46
RAB9A P51151 1/20 0.46
IDO1 P14902 1/20 0.45
ALDH1A1 P00352 6/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
MAPT P10636 5/20 0.44
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
XBP1 P17861 1/20 0.40
MAOA P21397 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345977 0.87 LMNA (0.51) MAOBLMNAHPGDSMN1; SMN2NPC1
SCHEMBL4342271 0.83 KMT2A (0.53) LMNASMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL4348031 0.81 MAOB (0.64) MAOBLMNAHPGDSMN1; SMN2IDO1
SCHEMBL4348536 0.81 LMNA (0.69) MAOBLMNAHPGDSMN1; SMN2NPC1
SCHEMBL4344050 0.78 MAOB (0.56) MAOBLMNAALOX12ALDH1A1MEN1
SCHEMBL6525136 0.78 KMT2A (0.51) LMNASMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL4348978 0.77 MEN1 (0.51) LMNAHPGDSMN1; SMN2NPC1TP53
SCHEMBL4349755 0.77 MAOB (0.58) MAOBLMNAHPGDSMN1; SMN2NPC1
SCHEMBL4346888 0.75 ALDH1A1 (0.54) MAOBLMNAHPGDSMN1; SMN2NPC1
SCHEMBL4349866 0.75 IDO1 (0.56) MAOBLMNAHPGDSMN1; SMN2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAOB 1008/4885LMNA 3160/4885HPGD 3561/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MAOB 677/4885LMNA 3661/4885HPGD 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.